clinical trial · NCT05236114
GEMINI-NSCLC: NSCLC Biomarker Study
Tempus AI·—·recruiting·n = 1,200
Non-Small Cell Lung CancerObservation
brief summary
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
started
Jun 22, 2022
primary completion
Jun 1, 2029
completion
Jun 1, 2029
last updated
Feb 5, 2026
official title
TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol